CN102197050A - 丙型肝炎抗体和其用途 - Google Patents

丙型肝炎抗体和其用途 Download PDF

Info

Publication number
CN102197050A
CN102197050A CN2008801313970A CN200880131397A CN102197050A CN 102197050 A CN102197050 A CN 102197050A CN 2008801313970 A CN2008801313970 A CN 2008801313970A CN 200880131397 A CN200880131397 A CN 200880131397A CN 102197050 A CN102197050 A CN 102197050A
Authority
CN
China
Prior art keywords
antibody
hcv
certain embodiments
cbh
people
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801313970A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·丰
凯克·振勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN102197050A publication Critical patent/CN102197050A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2008801313970A 2008-10-05 2008-10-05 丙型肝炎抗体和其用途 Pending CN102197050A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN102197050A true CN102197050A (zh) 2011-09-21

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801313970A Pending CN102197050A (zh) 2008-10-05 2008-10-05 丙型肝炎抗体和其用途

Country Status (12)

Country Link
US (1) US8858947B2 (enExample)
EP (1) EP2331573A4 (enExample)
JP (1) JP2012504602A (enExample)
KR (1) KR20110061624A (enExample)
CN (1) CN102197050A (enExample)
AU (1) AU2008362482A1 (enExample)
BR (1) BRPI0823197A2 (enExample)
CA (1) CA2738644A1 (enExample)
EA (1) EA201170353A1 (enExample)
IL (1) IL212040A0 (enExample)
MX (1) MX2011003613A (enExample)
WO (1) WO2010039154A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103113458A (zh) * 2013-02-27 2013-05-22 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705A (zh) * 2013-02-27 2013-06-26 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CN107011435A (zh) * 2016-06-01 2017-08-04 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN114907483A (zh) * 2016-03-22 2022-08-16 国家医疗保健研究所 人源化抗claudin-1抗体及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8592559B2 (en) 2009-10-30 2013-11-26 Toray Industries, Inc. Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereof
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
JP6158171B2 (ja) 2011-05-02 2017-07-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 合成ｃ型肝炎ゲノム、並びに、その製造方法及びその使用
BR112015002605B1 (pt) 2012-08-07 2023-03-07 Massachusetts Institute Of Technology Agente de anticorpo específico para o vírus da dengue, seu uso, kit, composição farmacêutica e método para sua produção
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
SG10201807826XA (en) 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
JPWO2015133467A1 (ja) * 2014-03-06 2017-04-06 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528140A (ja) 1998-11-05 2002-09-03 ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
CA2522379C (en) 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103113458A (zh) * 2013-02-27 2013-05-22 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705A (zh) * 2013-02-27 2013-06-26 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN114907483A (zh) * 2016-03-22 2022-08-16 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
CN114907483B (zh) * 2016-03-22 2024-07-26 国家医疗保健研究所 人源化抗claudin-1抗体及其用途
CN107011435A (zh) * 2016-06-01 2017-08-04 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6

Also Published As

Publication number Publication date
EP2331573A1 (en) 2011-06-15
BRPI0823197A2 (pt) 2015-06-23
EP2331573A4 (en) 2012-09-05
KR20110061624A (ko) 2011-06-09
AU2008362482A1 (en) 2010-04-08
MX2011003613A (es) 2011-08-03
IL212040A0 (en) 2011-06-30
US8858947B2 (en) 2014-10-14
WO2010039154A1 (en) 2010-04-08
CA2738644A1 (en) 2010-05-08
JP2012504602A (ja) 2012-02-23
EA201170353A1 (ru) 2011-12-30
US20120039846A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
CN102197050A (zh) 丙型肝炎抗体和其用途
KR101356350B1 (ko) 인간 사이토메갈바이러스 중화 항체 및 이의 용도
Tarr et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission
ES2529511T3 (es) Anticuerpos monoclonales anti-claudina 1 para la inhibición de la infección por virus de la hepatitis C
Drummer Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies
KR101407216B1 (ko) 인간 사이토메갈바이러스 중화 항체 및 이의 용도
ES2526907T3 (es) Anticuerpos neutralizantes de citomegalovirus humano y su uso
JP6483337B2 (ja) デングウイルス血清型１のｅタンパク質に対して特異性を有するヒトモノクローナル抗体およびその使用
US7727529B2 (en) Human monoclonal antibody Fab fragments directed against HCV E2 glycoprotein and endowed with in vitro neutralizing activity
US7537764B2 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
CA2339045A1 (en) Anti hepatitis c virus antibody and uses thereof
US20140322204A1 (en) Treatment and prevention of viral infections
CN102936284A (zh) 人抗狂犬病抗体及其用途
CN102084250A (zh) 用于检测目标反应与治疗黄病毒感染症状之组合物及方法
ES2377968T3 (es) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
CA2412460C (en) Human monoclonal antibody against hepatitis c virus e2 glycoprotein
JP2006504645A (ja) 立体構造及び直鎖状エピトープに対する抗体を用いたｈｃｖ感染の予防及び治療
CN109627297A (zh) 来自寨卡病毒e蛋白的中和表位及其应用
Moliner-Morro Characterisation of nanobodies directed against emerging viruses
Bai et al. Isolation of the neutralization ScFvs against HBV infection from the immunized population
HK1173979A (en) Improvements in or relating to treatment and prevention of hepatitis c viral infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110921

WD01 Invention patent application deemed withdrawn after publication